Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 10/20 | 0.54 |
| ▸ | BCHE | P06276 | 7/20 | 0.50 |
| ▸ | ACHE | P22303 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15759330 | 0.94 | ACSL1 (0.54) | XDHBCHEACHENPC1MAOA | |
| SCHEMBL12240977 | 0.93 | ALDH1A1 (0.55) | XDHBCHEACHENPC1MAOA | |
| SCHEMBL1795724 | 0.92 | XDH (0.56) | XDHBCHEACHE | |
| SCHEMBL1794001 | 0.90 | TAAR1 (0.45) | XDHBCHEACHERAB9A | |
| SCHEMBL12240964 | 0.88 | XDH (0.54) | XDHBCHEACHENPC1MAOA | |
| SCHEMBL1798063 | 0.87 | NPC1 (0.57) | BCHEACHENPC1MAOARAB9A | |
| SCHEMBL11049325 | 0.83 | ALDH2 (0.60) | XDHBCHEACHEMAOA | |
| SCHEMBL1793141 | 0.83 | SIGMAR1 (0.47) | XDHBCHEACHENPC1 | |
| SCHEMBL8961840 | 0.83 | XDH (0.65) | XDHBCHEACHE | |
| SCHEMBL2550117 | 0.83 | ACSL1 (0.67) | XDHBCHEACHENPC1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258682-A2 | Amino-substituted tricyclic derivatives and methods of use | Abbott Laboratories (US) | 2010-12-08 | — | — | EP | claimed |
| US-20080161281-A1 | Amino-Substituted Tricyclic Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | claimed |
| US-20050234031-A1 | Amino-substituted tricyclic derivatives and methods of use | ABBVIE INC. | 2005-10-20 | — | — | US | claimed |
| US-20050171079-A1 | Amino-substituted tricyclic derivatives and methods of use | SCHRIMPF MICHAEL R (US) | 2005-08-04 | — | — | US | claimed |
| US-8741659-B2 | Composition for measuring the binding affinity between nucleic acid and test substance, and use thereof | OSAKA UNIVERSITY (JP) | 2014-06-03 | — | — | US | disclosed |
| US-20120238029-A1 | COMPOSITION FOR MEASURING THE BINDING AFFINITY BETWEEN NUCLEIC ACID AND TEST SUBSTANCE, AND USE THEREOF | OSAKA UNIVERSITY (JP) | 2012-09-20 | — | — | US | disclosed |
| EP-2482076-A1 | Composition for measuring the binding affinity between nucleic acid and test substance, and use thereof | Osaka University (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-20110263041-A1 | COMPOSITION FOR MEASURING THE BINDING AFFINITY BETWEEN NUCLEIC ACID AND TEST SUBSTANCE, AND USE THEREOF | OSAKA UNIVERSITY (JP) | 2011-10-27 | — | — | US | disclosed |
| US-7951791-B2 | e.g. 2,7-bis-[(3R)-1-azabicyclo[2.2.2]octan-3-yloxy]-fluoren-9-one; alpha 7 Nicotinic acetylcholine receptors ligands; cognitive disorder, neurodegeneration, and neurodevelopmental disorders | ABBOTT LABORATORIES (US) | 2011-05-31 | — | — | US | disclosed |
| EP-2258682-A2 | Amino-substituted tricyclic derivatives and methods of use | Abbott Laboratories (US) | 2010-12-08 | — | — | EP | disclosed |
| EP-2175275-A1 | COMPOSITION FOR MEASURING THE BINDING AFFINITY BETWEEN NUCLEIC ACID AND SUBSTANCE, AND USE THEREOF | Osaka University (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-20080161281-A1 | Amino-Substituted Tricyclic Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
| US-7365193-B2 | Amino-substituted tricyclic derivatives and methods of use | ABBOTT LABORATORIES (US) | 2008-04-29 | — | — | US | disclosed |
| US-20050234031-A1 | Amino-substituted tricyclic derivatives and methods of use | ABBVIE INC. | 2005-10-20 | — | — | US | disclosed |
| US-20050171079-A1 | Amino-substituted tricyclic derivatives and methods of use | SCHRIMPF MICHAEL R (US) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234031-A1 | Amino-substituted tricyclic derivatives and methods of use | CHRNA1, CHRM1, GALR1 | XDH 49/4885BCHE 282/4885ACHE 89/4885 |
| US-20110263041-A1 | COMPOSITION FOR MEASURING THE BINDING AFFINITY BETWEEN NUCLEIC ACID AND TEST SUBSTANCE, AND USE THEREOF | RBM3, HNRNPA3, HNRNPAB | XDH 3309/4885BCHE 3922/4885ACHE 2074/4885 |
| US-20080161281-A1 | Amino-Substituted Tricyclic Derivatives and Methods of Use | CHRNA1, CHRM1, CHRNB1 | XDH 49/4885BCHE 175/4885ACHE 43/4885 |
| US-20050171079-A1 | Amino-substituted tricyclic derivatives and methods of use | CHRM1, CHRM3, CHRNA1 | XDH 242/4885BCHE 197/4885ACHE 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.